Shares of Incannex Healthcare Inc. (IXHL) are falling about 35 percent on Thursday morning trading following the announcement of an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea, and a securities purchase agreement with healthcare-dedicated...
Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company, announced that it has entered into a securities purchase agreement with healthcare-dedicated institutional investors for the issuance and sale of 2 million shares and accompanying warrants to purchase up to an aggregate of 2...
Incannex Healthcare (IXHL) announced that the FDA has granted Fast Track designation for IHL-42X, the company's oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea. The Fast Track designation was supported by safety, efficacy, and pharmacokinetic results from...
Incannex Healthcare Inc. (IXHL) Tuesday reported positive data from its Phase 2 study of PSX-001 a psilocybin-assisted psychotherapy treatment for generalised anxiety disorder. In the study, participants with generalised anxiety disorder were randomized to receive either PSX-00 or placebo. Results...
Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company, on Friday announced that its board has approved a share repurchase program of up to $20 million of its outstanding common stock. The company said buybacks may be executed through open-market purchases, privately negotiated...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.